Genomic Health Plans to Move Next-Gen Sequencing into Commercial Test Development within Two Years | GenomeWeb

By Monica Heger

This story was originally published Feb. 17.

Genomic Health plans to eventually move its molecular diagnostics testing platform from quantitative RT-PCR to next-generation sequencing, the company reported this month in an earnings call with investors.

Near term, Genomic Health expects next-gen sequencing to have an impact on biomarker identification, but over the next two to four years, the company plans to move the technology into its commercial development process.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.